Standpoints

Please include Keytruda (pembrolizumab) in the indication ca stomach and GEJ in the case of a final decision of the Ministry of Health of the Slovak Republic from 1.1.2026 in the DRG as an attributable item.

NA - Keytruda (pembrolizumab) is pending ID35514 in the indication in question

patients with HER2-negative gastric cancer and GEJ requiring first-line treatment for locally advanced, unresectable or metastatic cancer during hospitalisation according to the above IO

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.

Requirement for PP medicine - tenecteplase

The opinion is set out in feedback number 659 - https://www.cksdrg.sk/sk/spatna-vazba/stanoviska/659

Please include Keytruda (pembrolizumab) in the case of a final decision of the Ministry of Health of the Slovak Republic from 1.1.2026 in the DRG as a creditable item

on - ID35033 is pending in the indication in question, with an expected date of inclusion in the ZKL in 2025

patients with oesophageal cancer requiring first-line treatment for locally advanced, unresectable or metastatic cancer during hospitalisation

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.

The indication according to clinical trial KN826 in the following wording will be included in the ZKL by a final decision of the Ministry of Health as of 1.5.2025. Keytruda, in combination with or without chemotherapy and bevacizumab, is indicated for the first-line treatment of persistent, recurrent or metastatic cervical cancer in adults who have not been treated with chemotherapy (with the exception of its concomitant use as a radiosensitising agent) and whose tumours show PD-L1 expression with a CPS ≥ 1, for a maximum of 24 months. The combination of pembrolizumab with chemotherapy alone is covered only for patients unsuitable for treatment with bevacizumab.

Please include Keytruda (pembrolizumab) as a DRG creditable item from 1.1.2026.

Indication: patients with ca cervix requiring treatment during hospitalization according to the above IO.

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.

PP formation - von-Willebrand factor

Proposal approved